Method and apparatus for photoactivation medicament treatment

Abstract

A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.

Description

technical field

[0001] The present invention relates generally to prostate treatment systems for use in the treatment of prostate tissue in combination with photoactive agents, and more particularly to transurethral devices for use in the treatment of benign prostatic hyperplasia (BPH) in combination with photoactivatable drugs. Background technique

[0002] Benign prostatic hyperplasia (BPH) and prostate cancer are common conditions among older men. In people with BPH, an enlarged prostate can press on the urethra causing urinary tract obstruction, which makes urination difficult. An enlarged prostate can also cause stones in the urethra, inflammation, infection, and in some cases, kidney failure.

[0003] Primary treatments for BPH include surgical procedures such as prostatectomy or transurethral resection of the prostate. These treatments require the patient to be hospitalized, which can be a financial burden for the patient. Furthermore, the surgical procedure can le...

Images